NephroGenex Investor Center

About Us

NephroGenex is an innovator in the development of novel drugs to treat kidney disease, with a first indication in diabetic nephropathy. The Company has positioned its Phase 3 Pyridorin program for success by securing from FDA a fast track designation and Special Protocol Assessment for a unique endpoint and patient group. We believe Pyridorin has potential to be a breakthrough therapy in a disease for which there are few treatment options.

Upcoming Events

There are no scheduled events at this time. Please check back later.